Decreased levels of circulating CD4+CD25+Foxp3+ regulatory T cells in patients with primary antiphospholipid syndrome
- PMID: 23354908
- DOI: 10.1007/s10875-012-9857-y
Decreased levels of circulating CD4+CD25+Foxp3+ regulatory T cells in patients with primary antiphospholipid syndrome
Abstract
Introduction: CD4(+)CD25(+)Foxp3(+) regulatory T (Treg) cell dysfunction has been documented in various autoimmune disorders, but not in antiphospholipid syndrome (APS) so far.
Methods: In this cross-sectional study, we aim to investigate CD4(+)CD25(+)Foxp3(+) Treg cells, CD3(+)CD19(-) T cells and CD3(-)CD19(+) B cells in patients with primary APS and healthy controls. Cell subtypes were immunophenotyped using specific monoclonal antibodies (anti-CD3 CY5, anti-CD4 FITC, anti-CD25, anti-Foxp3, anti-CD19 PE) and flow cytometry.
Results: Twenty patients with APS and 20 age- and sex-matched controls were studied. The percentage of total lymphocytes, activated Th cells (CD4+CD25+), Treg cells and CD3(-)CD19(+) B cells were found significantly lower in APS patients as compared to controls (all p < 0.05).
Conclusion: A dysfunction in CD4(+)CD25(+)Foxp3(+) Treg cells may represent one of the mechanisms leading to autoimmunity in APS patients. The decreased number of CD3(-)CD19(+) B cells of APS patients warrants further elucidation.
Similar articles
-
Patients with systemic lupus erythematosus and secondary antiphospholipid syndrome have decreased numbers of circulating CD4⁺CD25⁺Foxp3⁺ Treg and CD3⁻CD19⁺ B cells.Rev Bras Reumatol. 2014 May-Jun;54(3):241-6. Rev Bras Reumatol. 2014. PMID: 25054604 English, Portuguese.
-
Regulatory T cells in Behçet's disease: is there a correlation with disease activity? Does regulatory T cell type matter?Rheumatol Int. 2013 Dec;33(12):3049-54. doi: 10.1007/s00296-013-2835-8. Epub 2013 Aug 3. Rheumatol Int. 2013. PMID: 23912800
-
Foxp3(high) and Foxp3(low) Treg cells differentially correlate with T helper 1 and natural killer cells in peripheral blood.Hum Immunol. 2011 Aug;72(8):621-6. doi: 10.1016/j.humimm.2011.03.013. Epub 2011 May 11. Hum Immunol. 2011. PMID: 21600259
-
Forkhead box P3: the peacekeeper of the immune system.Int Rev Immunol. 2014 Mar;33(2):129-45. doi: 10.3109/08830185.2013.863303. Epub 2013 Dec 19. Int Rev Immunol. 2014. PMID: 24354325 Review.
-
Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases.Nat Rev Immunol. 2010 Dec;10(12):849-59. doi: 10.1038/nri2889. Nat Rev Immunol. 2010. PMID: 21107346 Free PMC article. Review.
Cited by
-
Preliminary Study on the Imbalance Between Th17 and Regulatory T Cells in Antiphospholipid Syndrome.Front Immunol. 2022 May 6;13:873644. doi: 10.3389/fimmu.2022.873644. eCollection 2022. Front Immunol. 2022. PMID: 35603166 Free PMC article.
-
Emerging and Novel Functions of Complement Protein C1q.Front Immunol. 2015 Jun 29;6:317. doi: 10.3389/fimmu.2015.00317. eCollection 2015. Front Immunol. 2015. PMID: 26175731 Free PMC article. Review.
-
Peripheral B-Cell Subset Distribution in Primary Antiphospholipid Syndrome.Int J Mol Sci. 2018 Feb 16;19(2):589. doi: 10.3390/ijms19020589. Int J Mol Sci. 2018. PMID: 29462939 Free PMC article.
-
Age-Related Differences in Percentages of Regulatory and Effector T Lymphocytes and Their Subsets in Healthy Individuals and Characteristic STAT1/STAT5 Signalling Response in Helper T Lymphocytes.J Immunol Res. 2015;2015:352934. doi: 10.1155/2015/352934. Epub 2015 Oct 7. J Immunol Res. 2015. PMID: 26525134 Free PMC article.
-
Immunosuppressive Treatment in Antiphospholipid Syndrome: Is It Worth It?Biomedicines. 2021 Feb 1;9(2):132. doi: 10.3390/biomedicines9020132. Biomedicines. 2021. PMID: 33535377 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous